Sun Pharma Q4 profit declines 37%: Should you buy, sell or hold?
Updated : 2020-05-28 13:44:07
Sun Pharma in March quarter FY20 posted a consolidated profit of Rs 399.8 crore. It registered a decline of 37.1 percent year-on-year due to a one-time loss of Rs 260.6 crore. However, consolidated revenue during the quarter rose 14.3 percent year-on-year to Rs 8,184.9 crore, beating CNBC-TV18 estimate of Rs 8,015.8 crore. The pharmaceutical giant's stock rose over 1 percent after the earnings announcement. So should you buy, sell, or hold the stock post Q4? Here's what brokerages say: